期刊文献+

Development and validation of RP-HPLC method for estimation of eplerenone in spiked human plasma 被引量:2

Development and validation of RP-HPLC method for estimation of eplerenone in spiked human plasma
下载PDF
导出
摘要 A rapid and simple high performance liquid chromatography (HPLC) mcthod wiih a UV detection (241 nm) was developed and validated for estimation of eplerenone from spiked human plasma. The analyte and the internal standard (valdecoxib) were extracted with a mixture of dichloromethane and diethyl ether. The chromatographic separation was performed on a HiQSil C-18HS column (250 mm × 4.6 mm, 5 um) with a mobile phase consisting of acetonitrile:water (50:50, v/v) at flow rate of 1 mL/min. The calibration curve was linear in the range 100 3200 ng/mL and the heteroscedasticity was minimized by using weighted least squares regression with weighting factor I/X. A rapid and simple high performance liquid chromatography (HPLC) mcthod wiih a UV detection (241 nm) was developed and validated for estimation of eplerenone from spiked human plasma. The analyte and the internal standard (valdecoxib) were extracted with a mixture of dichloromethane and diethyl ether. The chromatographic separation was performed on a HiQSil C-18HS column (250 mm × 4.6 mm, 5 um) with a mobile phase consisting of acetonitrile:water (50:50, v/v) at flow rate of 1 mL/min. The calibration curve was linear in the range 100 3200 ng/mL and the heteroscedasticity was minimized by using weighted least squares regression with weighting factor I/X.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2012年第5期390-393,共4页 药物分析学报(英文版)
关键词 EPLERENONE Liquid-liquidextraction Weighted regression HPLC-UV Eplerenone Liquid-liquidextraction Weighted regression HPLC-UV
  • 相关文献

参考文献7

  • 1J.A. Spetrus, J. Tooely, P. Jones, et al., Expanding the outcomes in clinical trils of heart failure: the quality of life and economic components of EPHESUS (eplerenone's neurohormonal efficiency and survival study), Am. Heart J. 143 (4) (2002) 636-642.
  • 2J.A. Delyani, R. Rocha, C.S. Cook, et al., Eplerenone: a selective aldosterone receptor antagonist (SARA), Cardiovasc. Ther. 19 (3) (2001) 185-200.
  • 3V.P. Rane, K.R. Patil, J.N. Sangshetti, et al., Stability-indicating RP-HPLC method for analysis of eplerenone in the bulk drug and in pharmaceutical dosage form, Acta Chromatogr. 21 (4) (2009) 619-629.
  • 4S. Sonawane, P. Gide, An experimental design approach for the forced degradation studies and development of a stability-indicating method for eplerenone in tablets, J. Liq. Chromatogr. Relat. Technol. 34 (17) (2011) 2020-2031.
  • 5J.Y. Zhang, D.M. Fast, A.P. Breau, Development and validation of a liquid chromatography-tandem mass spectrometric assay for eplerenone and its hydrolyzed metabolite in human plasma, J. Chromatogr. B 787 (2) (2003) 333-344.
  • 6J.Y. Zhang, D.M. Fast, A.P. Breau, A validated SPE-LC/MS assay for eplerenone and its hydrolyzed metabolite in human urine, J. Pharm. Biomed. Anal. 31 (1) (2003) 103-115.
  • 7US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, (http://www.fda.gov/cder/guidance/index.htm) (visited on 16.11.11).

同被引文献4

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部